Table 1 Baseline characteristics of participants

From: Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study

 

10  µg PPV-06

50  µg PPV-06

Placebo

 

(n = 9)

(n = 9)

(n = 6)

Age (y); mean (SD)

58.3 (5.96)

57.9 (9.41)

51.3 (8.41)

Sex (Female/Male); n (%)

4 (44.4)/5 (55.5)

3 (33.3)/6 (66.7)

3 (50)/3 (50)

BMI (kg/m2); (SD)

27.80 (2.557)

23.9 (2.50)

24.63 (3.24)

Time for diagnosis OA to first study dose (y)

3.54 (2.83)

4.25 (3.52)

6.79 (7.63)

Kellgren-Lawrence grade, n (%)

   

2

6 (66.2)

5 (55.6)

5 (83.9)

3

1 (11.1)

3 (33.3)

1 (16.7)

4

2 (22.2)

1 (11.1)

0

Pain on Numeric Rating Scale (NRS) at Baseline; mean (SD)

4.44 (2.24)

4.11 (2.71)

6.0 (2.97)

  1. The participants’ baseline characteristics are shown for the 24 participants. Source data are provided as a Source Data file. BMI body mass index, OA osteoarthritis, SD standard deviation.
Back to article page